Microvillus Inclusion Disease (MVID) Market Outlook

Thelansis’s “Microvillus Inclusion Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Microvillus Inclusion Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Microvillus Inclusion Disease (MVID) Overview

Microvillus inclusion disease (MVID) is an ultra-rare, life-threatening congenital enteropathy caused by autosomal recessive loss-of-function mutations in MYO5B — encoding myosin Vb, critical for apical membrane trafficking and brush border formation — and less commonly STX3 and STXBP2, disrupting enterocyte polarity and microvillus assembly. The pathological hallmark is abnormal intracellular accumulation of microvilli within membrane-bound inclusions and brush border atrophy, causing near-total loss of intestinal absorptive capacity. Neonates present within hours to days of birth with profuse secretory diarrhoea persisting despite bowel rest, severe dehydration, and life-threatening electrolyte imbalances, necessitating immediate parenteral nutrition. Diagnosis is established through transmission electron microscopy demonstrating pathognomonic microvillus inclusions, supported by PAS-positive intracytoplasmic staining, and confirmed by comprehensive enteropathy gene panel testing encompassing MYO5B, STX3, and STXBP2. No curative medical therapy currently exists; survival depends on long-term total parenteral nutrition, with attendant risks of line-associated sepsis, intestinal failure-associated liver disease, and thrombosis. Small intestinal or combined liver-intestine transplantation offers the only definitive therapeutic option. Prognosis without transplantation is extremely poor; multidisciplinary intestinal rehabilitation, meticulous line care, and family-centred psychosocial support are indispensable to compassionate long-term management.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)